MA27190A1 - Derives de tropane servant de modulateurs de ccr5 - Google Patents

Derives de tropane servant de modulateurs de ccr5

Info

Publication number
MA27190A1
MA27190A1 MA27883A MA27883A MA27190A1 MA 27190 A1 MA27190 A1 MA 27190A1 MA 27883 A MA27883 A MA 27883A MA 27883 A MA27883 A MA 27883A MA 27190 A1 MA27190 A1 MA 27190A1
Authority
MA
Morocco
Prior art keywords
modulators
ccr5
treatment
present
tropane derivatives
Prior art date
Application number
MA27883A
Other languages
English (en)
Inventor
Patricia Ann Basford
Stefan Colin John Taylor
Peter Thomas Stephenson
Anthony Wood
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0208071.1A external-priority patent/GB0208071D0/en
Priority claimed from GB0301575A external-priority patent/GB0301575D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of MA27190A1 publication Critical patent/MA27190A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)

Abstract

DEPOSANT Société dite : PFIZER INC. REVENDICATION DE PRIORITES GB 8 Avril 2002 0208071.1 GB 23 Janvier 2003 0301575.7 Voir en annexe le titre de l'invention et le texte de l'abrégé Dérivés de tropane servant de modulateurs de CCR5 La présente invention propose des composés de formule (I) dans laquelle X, Y, R1, R2 et R3 répondent aux définitions indiquées. Les composés de la présente invention sont des modulateurs, notamment des antagonistes, de l'activité des récepteurs de chimiokines CCR5. Des modulateurs du récepteur CCR5 peuvent être utiles dans le traitement de diverses maladies et affections inflammatoires, et dans le traitement de l'infection par le VIH et par des rétrovirus génétiquement apparentés.
MA27883A 2002-04-08 2004-09-29 Derives de tropane servant de modulateurs de ccr5 MA27190A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0208071.1A GB0208071D0 (en) 2002-04-08 2002-04-08 Tropane derivatives useful in therapy
GB0301575A GB0301575D0 (en) 2003-01-23 2003-01-23 Tropane derivatives useful in therapy

Publications (1)

Publication Number Publication Date
MA27190A1 true MA27190A1 (fr) 2005-01-03

Family

ID=28793308

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27883A MA27190A1 (fr) 2002-04-08 2004-09-29 Derives de tropane servant de modulateurs de ccr5

Country Status (40)

Country Link
EP (1) EP1492789B1 (fr)
JP (2) JP3793200B2 (fr)
KR (1) KR100734685B1 (fr)
CN (1) CN1324025C (fr)
AP (1) AP1789A (fr)
AR (1) AR039383A1 (fr)
AT (1) ATE328882T1 (fr)
AU (1) AU2003214503B2 (fr)
BR (1) BR0309118A (fr)
CA (1) CA2481482C (fr)
CR (1) CR7514A (fr)
CU (1) CU23282A3 (fr)
CY (1) CY1106114T1 (fr)
DE (1) DE60305903T2 (fr)
DK (1) DK1492789T3 (fr)
DO (1) DOP2003000624A (fr)
EA (1) EA007590B1 (fr)
ES (1) ES2263960T3 (fr)
GE (1) GEP20074210B (fr)
HN (1) HN2003000114A (fr)
HR (1) HRP20040940A2 (fr)
IL (1) IL164261A0 (fr)
IS (1) IS2577B (fr)
MA (1) MA27190A1 (fr)
MX (1) MXPA04009220A (fr)
MY (1) MY134223A (fr)
NI (1) NI200300053A (fr)
NO (1) NO329674B1 (fr)
NZ (1) NZ535452A (fr)
OA (1) OA12798A (fr)
PA (1) PA8570801A1 (fr)
PE (1) PE20040082A1 (fr)
PL (1) PL372968A1 (fr)
PT (1) PT1492789E (fr)
RS (1) RS51550B (fr)
SI (1) SI1492789T1 (fr)
TN (1) TNSN04194A1 (fr)
TW (1) TWI280130B (fr)
UY (1) UY27752A1 (fr)
WO (1) WO2003084954A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51550B (sr) * 2002-04-08 2011-06-30 Pfizer Inc. Derivati tropana kao modulatori ccr5
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
EP1786816A4 (fr) 2003-09-10 2009-11-04 Virochem Pharma Inc Composes de spirohydantoine et procedes de modulation de l'activite des recepteurs de chimiokine
GB0323236D0 (en) * 2003-10-03 2003-11-05 Pfizer Ltd Chemical compounds
MXPA06003749A (es) * 2003-10-03 2006-06-14 Pfizer Derivados de tropano.
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US8131026B2 (en) 2004-04-16 2012-03-06 Validity Sensors, Inc. Method and apparatus for fingerprint image reconstruction
DE602005022900D1 (de) 2004-10-04 2010-09-23 Validity Sensors Inc Fingerabdruckerfassende konstruktionen mit einem substrat
WO2006064340A2 (fr) * 2004-12-13 2006-06-22 Pfizer Limited Elaboration de n-acyl beta-aminoaldehydes
WO2008063600A2 (fr) * 2006-11-17 2008-05-29 Concert Pharmaceuticals Inc. Dérivés de triazolyle tropane
AU2008239966C1 (en) * 2007-04-13 2012-03-29 Dong Wha Pharmaceutical Co., Ltd. Aspartate of 1-cyclopropyl-6-fluoro-7-(8-methoxyimino-2,6-diaza- spiro[3.4]oct-6-yl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid, method for preparing the same, and antimicrobial pharmaceutical composition comprising the same
US7947710B2 (en) 2007-08-27 2011-05-24 Theravance, Inc. Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
CN101712679B (zh) * 2008-10-08 2013-04-10 中国科学院上海药物研究所 一种酰胺类化合物、其药物组合物及其制备方法和用途
CN102639504A (zh) * 2009-11-21 2012-08-15 弗·哈夫曼-拉罗切有限公司 杂环抗病毒化合物
US8674115B2 (en) 2009-12-23 2014-03-18 Ironwood Pharmaceuticals, Inc. CRTH2 modulators
MX2012011415A (es) 2010-04-02 2013-02-26 Phivco 1 Llc Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico.
US20130259830A1 (en) 2010-07-12 2013-10-03 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009137A1 (fr) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Modulateurs de crth2
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
WO2013024022A1 (fr) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour traiter l'hypertension pulmonaire
CN103159754A (zh) * 2011-12-19 2013-06-19 中国科学院上海药物研究所 一种氨基丙基取代托烷胺类化合物、其药物组合物及其制备方法和用途
JP6146990B2 (ja) * 2012-11-16 2017-06-14 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたｃｆｔｒ増強物質
GB201321749D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321748D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
HK1249893A1 (zh) 2015-03-31 2018-11-16 Vertex Pharmaceuticals (Europe) Limited 氘代vx-661
EP3352758A4 (fr) 2015-09-25 2018-08-01 Vertex Pharmaceuticals (Europe) Limited Potentialisateurs cftr deutérés
JP2017105824A (ja) * 2017-02-10 2017-06-15 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたｃｆｔｒ増強物質
CN117924170A (zh) 2017-12-01 2024-04-26 弗特克斯药品有限公司 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法
EP3768256A4 (fr) 2018-03-19 2021-11-24 Emory University Inhibiteurs d'entrée pantropique
JP6654223B2 (ja) * 2018-08-13 2020-02-26 バーテックス ファーマシューティカルズ （ヨーロッパ） リミテッド 重水素化されたｃｆｔｒ増強物質
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
WO2001080106A1 (fr) * 2000-04-19 2001-10-25 Satoshi Yamazaki Procede de diffusion d'outil publicitaire et support magnetique pour le logiciel
HRP20020938B1 (en) * 2000-05-26 2011-05-31 Pfizer Inc. Tropane derivatives useful in therapy
RS51550B (sr) * 2002-04-08 2011-06-30 Pfizer Inc. Derivati tropana kao modulatori ccr5

Also Published As

Publication number Publication date
CU23282A3 (es) 2008-06-30
EA007590B1 (ru) 2006-12-29
HRP20040940A2 (en) 2005-04-30
KR100734685B1 (ko) 2007-07-02
RS88804A (sr) 2006-12-15
GEP20074210B (en) 2007-10-10
TW200403242A (en) 2004-03-01
CN1324025C (zh) 2007-07-04
AU2003214503B2 (en) 2008-08-07
WO2003084954A1 (fr) 2003-10-16
HN2003000114A (es) 2004-05-05
SI1492789T1 (sl) 2006-10-31
TWI280130B (en) 2007-05-01
IL164261A0 (en) 2005-12-18
AU2003214503A1 (en) 2003-10-20
OA12798A (en) 2006-07-10
NI200300053A (es) 2005-11-01
TNSN04194A1 (fr) 2007-03-12
EA200401167A1 (ru) 2005-04-28
DOP2003000624A (es) 2003-10-15
MXPA04009220A (es) 2005-09-30
ATE328882T1 (de) 2006-06-15
UY27752A1 (es) 2003-11-28
DK1492789T3 (da) 2006-09-11
JP2005532285A (ja) 2005-10-27
JP4571078B2 (ja) 2010-10-27
NO20044615L (no) 2004-10-26
RS51550B (sr) 2011-06-30
CR7514A (es) 2004-11-08
CA2481482C (fr) 2009-11-10
CN1646526A (zh) 2005-07-27
DE60305903D1 (de) 2006-07-20
EP1492789B1 (fr) 2006-06-07
AP2004003147A0 (en) 2004-09-30
JP2006182784A (ja) 2006-07-13
AR039383A1 (es) 2005-02-16
IS2577B (is) 2010-02-15
DE60305903T2 (de) 2007-03-08
PT1492789E (pt) 2006-09-29
JP3793200B2 (ja) 2006-07-05
CA2481482A1 (fr) 2003-10-16
NZ535452A (en) 2006-11-30
PE20040082A1 (es) 2004-03-20
NO329674B1 (no) 2010-11-29
CY1106114T1 (el) 2011-06-08
IS7453A (is) 2004-09-16
EP1492789A1 (fr) 2005-01-05
PL372968A1 (en) 2005-08-08
HK1076102A1 (en) 2006-01-06
BR0309118A (pt) 2005-02-01
KR20040099420A (ko) 2004-11-26
PA8570801A1 (es) 2004-11-26
MY134223A (en) 2007-11-30
ES2263960T3 (es) 2006-12-16
AP1789A (en) 2007-10-05

Similar Documents

Publication Publication Date Title
TNSN04194A1 (fr) Derives de tropane servant de modulateurs de ccr5
MA27452A1 (fr) Derives d&#39;indole servant d&#39;agonistes beta-2
TW200519112A (en) Tropane derivatives
EA200701036A1 (ru) Лактамные соединения и их применение в качестве фармацевтических препаратов
MA27142A1 (fr) Derives de piperazine a activite antagoniste des recepteurs ccr1
MA27174A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4.
ATE302005T1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
ATE286500T1 (de) 1,2,3,4-tetrahydroisochinolin-derivate
EA200700117A1 (ru) N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
MA27451A1 (fr) Derives de thiazole pour le traitement de troubles neurodegeneratifs
PT1000035E (pt) 6-fenilfenantridinas substituidas
ATE302606T1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
MA31867B1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA27141A1 (fr) DERIVES DE 3-AZABICYCLO[3.1.0]HEXANE SERVANT D&#39;ANTAGONISTES DES RECEPTEURS D&#39;OPIOiDES
MA29213B1 (fr) Quinolones a substitution macrolones - amino
ATE293448T1 (de) Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten
MA27840A1 (fr) Derives de (2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propylphenyle servant d&#39;agonistes beta2
TNSN08137A1 (fr) Derives de carboxamides servant d&#39;antagonistes des recepteurs muscariniques
NO20020282L (no) Nytt difenyl-piperidinderivat
DE602004011204D1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
MA26953A1 (fr) Derives de pipérazine pontés.
PT775118E (pt) Derivados de benzimidazole com actividade dopaminergica
TR200200969T2 (tr) Karbonilamino türevlerinin CNS bozukluklarına karşı kullanılması
CO5180558A1 (es) Derivados de n-[3-((piperidin-1-il)metil)-4-(fenil o hetero- ciclil)ciclopent-1-il]]amina utiles como moduladores de actividad del receptor de la quimioquina
MA26876A1 (fr) Mesylate et formes polymorphes de 4-amino-6, 7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydro-isoquinol-2-yl)-5-(2-pyridyl)quinazoline